ORIGINAL ARTICLE

Longitudinal amyloid cognitive composite in preclinical Alzheimer’s disease

Young Ju Kim

orcid.org/0000-0003-2927-6724

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Contribution: Conceptualization (equal), Formal analysis (equal), Methodology (equal), Resources (equal), Writing - original draft (equal), Writing - review & editing (equal)

Search for more papers by this author

Alice Hahn,

Alice Hahn

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Contribution: Conceptualization (equal), Formal analysis (equal), Methodology (equal), Resources (equal), Writing - original draft (equal), Writing - review & editing (equal)

Search for more papers by this author

Yu Hyun Park,

Yu Hyun Park

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Contribution: Formal analysis (equal), Methodology (equal), Resources (equal)

Search for more papers by this author

Duk L. Na,

Duk L. Na

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Stem Cell & Regenerative Medicine Institute, Seoul, Korea

Contribution: Resources (equal)

Search for more papers by this author

Juhee Chin,

Corresponding Author

Juhee Chin

[email protected]

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Correspondence

Sang Won Seo and Juhee Chin, Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.

Emails: [email protected] (S.W.S.); [email protected] (J.C.)

Contribution: Conceptualization (equal), Resources (equal), Supervision (equal), Writing - review & editing (equal)

Search for more papers by this author

Sang Won Seo,

Corresponding Author

Sang Won Seo

[email protected]

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Samsung Alzheimer Research Center, Seoul, Korea

Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea

Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea

Correspondence

Sang Won Seo and Juhee Chin, Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.

Emails: [email protected] (S.W.S.); [email protected] (J.C.)

Contribution: Conceptualization (equal), Funding acquisition (lead), Resources (equal), Supervision (equal), Writing - review & editing (equal)

Search for more papers by this author

Young Ju Kim,

Young Ju Kim

orcid.org/0000-0003-2927-6724

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Contribution: Conceptualization (equal), Formal analysis (equal), Methodology (equal), Resources (equal), Writing - original draft (equal), Writing - review & editing (equal)

Search for more papers by this author

Alice Hahn,

Alice Hahn

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Contribution: Conceptualization (equal), Formal analysis (equal), Methodology (equal), Resources (equal), Writing - original draft (equal), Writing - review & editing (equal)

Search for more papers by this author

Yu Hyun Park,

Yu Hyun Park

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Contribution: Formal analysis (equal), Methodology (equal), Resources (equal)

Search for more papers by this author

Duk L. Na,

Duk L. Na

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Stem Cell & Regenerative Medicine Institute, Seoul, Korea

Contribution: Resources (equal)

Search for more papers by this author

Juhee Chin,

Corresponding Author

Juhee Chin

[email protected]

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Correspondence

Sang Won Seo and Juhee Chin, Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.

Emails: [email protected] (S.W.S.); [email protected] (J.C.)

Contribution: Conceptualization (equal), Resources (equal), Supervision (equal), Writing - review & editing (equal)

Search for more papers by this author

Sang Won Seo,

Corresponding Author

Sang Won Seo

[email protected]

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Neuroscience Center, Samsung Medical Center, Seoul, Korea

Samsung Alzheimer Research Center, Seoul, Korea

Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea

Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea

Correspondence

Sang Won Seo and Juhee Chin, Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.

Emails: [email protected] (S.W.S.); [email protected] (J.C.)

Contribution: Conceptualization (equal), Funding acquisition (lead), Resources (equal), Supervision (equal), Writing - review & editing (equal)

Search for more papers by this author

First published: 31 December 2021

https://doi.org/10.1111/ene.15241

Citations: 2

Young Ju Kim and Alice Hahn contributed equally to this work.

Funding information

This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare and Ministry of Science and Information and Communication Technologies (ICT), Republic of Korea (grant number: HU20C0111); a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI19C1132); a fund (2021-ER1006-00) by Research of Korea Disease Control and Prevention Agency; Institute of Information & communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (MSIT) (No.2021-0-02068, Artificial Intelligence Innovation Hub); Future Medicine 20*30 Project of the Samsung Medical Center [#SMX1220021].

[Correction added on 05 March 2022, after first online publication: ‘Future Medicine 20*30 Project of the Samsung Medical Center’ was added to the funding information.]

Share a link

Email
Wechat
Bluesky

Abstract

Background and purpose

Previous studies have developed several cognitive composites in preclinical Alzheimer disease (AD). However, more sensitive measures to track cognitive changes and therapeutic efficacy in preclinical AD are needed considering the diverse sociocultural and linguistic backgrounds. This study developed a composite score that can sensitively detect the amyloid-β (Aβ)-related cognitive trajectory of preclinical AD using Korean data.

Methods

A total of 196 cognitively normal participants who underwent amyloid positron emission tomography were followed-up with neuropsychological assessments. We developed the Longitudinal Amyloid Cognitive Composite in Preclinical AD (LACPA) using the linear mixed-effects model (LMM) and z scores. The LMM was also used to investigate the longitudinal sensitivity of the LACPA and the association between time-varying brain atrophy and the LACPA.

Results

Considering the group-time interaction effects of each subtest, the Seoul Verbal Learning Test-Elderly version immediate recall/delayed recall/recognition, the Korean Trail Making Test B Time, and the Korean Mini-Mental State Examination were selected as components of the LACPA. The LACPA exhibited a significant group-time interaction effect between the Aβ+ and Aβ− groups (t = −3.288, p = 0.001). Associations between time-varying LACPA and brain atrophy were found in the bilateral medial temporal, right lateral parietal, and right lateral frontal regions, and hippocampal volume.

Conclusions

The LACPA may contribute to reduction in time and financial burden when monitoring Aβ-related cognitive decline and therapeutic efficacy of the disease-modifying agents specifically targeting Aβ in secondary prevention trials.

CONFLICT OF INTEREST

The authors declare no financial or other conflicts of interest.

Open Research

DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supporting Information

REFERENCES

1Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2): 207-216.
10.1016/S1474-4422(12)70291-0
CAS PubMed Web of Science® Google Scholar
2Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367(9): 795-804.
10.1056/NEJMoa1202753
CAS PubMed Web of Science® Google Scholar
3Dore V, Villemagne VL, Bourgeat P, et al. Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 2013; 70(7): 903-911.
10.1001/jamaneurol.2013.1062
PubMed Web of Science® Google Scholar
4Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018; 17(3): 241-250.
10.1016/S1474-4422(18)30028-0
PubMed Web of Science® Google Scholar
5Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013; 12(4): 357-367.
10.1016/S1474-4422(13)70044-9
CAS PubMed Web of Science® Google Scholar
6Weller RO, Love S, Nicoll JAR. Elimination of Amyloid β from the Brain, its Failure in Alzheimer's Disease and Implications for Therapy. In: DW Dickson, RO Weller, eds. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd ed. Wiley-Blackwell; 2011: 97-101.
10.1002/9781444341256.ch12
Google Scholar
7Aisen PS, Sperling RA, Cummings J, et al. The trial-ready cohort for preclinical/prodromal Alzheimer's disease (TRC-PAD) project: an overview. J Prev Alzheimers Dis. 2020; 7(4): 208-212.
10.14283/jpad.2020.45
CAS PubMed Web of Science® Google Scholar
8 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease. https://www.fda.gov/media/110903/download. Accessed 15 June 2021.
Google Scholar
9Schneider LS, Goldberg TE. Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimers Dement (Amst). 2020; 12(1):e12017.
10.1002/dad2.12017
PubMed Web of Science® Google Scholar
10Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014; 71(8): 961-970.
10.1001/jamaneurol.2014.803
PubMed Web of Science® Google Scholar
11Langbaum JB, Hendrix SB, Ayutyanont N, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10(6): 666-674.
10.1016/j.jalz.2014.02.002
PubMed Web of Science® Google Scholar
12Barnes LL, Wilson RS, Li Y, et al. Racial differences in the progression of cognitive decline in Alzheimer disease. Am J Geriatr Psychiatry. 2005; 13(11): 959-967.
10.1097/00019442-200511000-00006
PubMed Web of Science® Google Scholar
13de Souza-Talarico JN, de Carvalho AP, Brucki SM, Nitrini R, Ferretti-Rebustini RE. Dementia and cognitive impairment prevalence and associated factors in indigenous populations: a systematic review. Alzheimer Dis Assoc Disord. 2016; 30(3): 281-287.
10.1097/WAD.0000000000000140
PubMed Web of Science® Google Scholar
14Manly JJ, Schupf N, Tang MX, Stern Y. Cognitive decline and literacy among ethnically diverse elders. J Geriatr Psychiatry Neurol. 2005; 18(4): 213-217.
10.1177/0891988705281868
PubMed Web of Science® Google Scholar
15Hahn A, Kim YJ, Kim HJ, et al. The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease. Sci Rep. 2020; 10(1): 1-11.
10.1038/s41598-020-70386-3
PubMed Web of Science® Google Scholar
16Lee JS, Lee H, Park S, et al. Association between APOE epsilon2 and Abeta burden in patients with Alzheimer- and vascular-type cognitive impairment. Neurology. 2020; 95(17): e2354-e2365.
10.1212/WNL.0000000000010811
CAS PubMed Web of Science® Google Scholar
17Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011; 10(5): 424-435.
10.1016/S1474-4422(11)70077-1
CAS PubMed Web of Science® Google Scholar
18Curtis C, Gamez JE, Singh U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015; 72(3): 287-294.
10.1001/jamaneurol.2014.4144
PubMed Web of Science® Google Scholar
19Kang Y, Jahng S, Na DL. (SNSB-II): Professional Manual, 2nd ed. Human brain research & consulting co. 2012.
Google Scholar
20Kang SH, Park YH, Lee D, et al. The cortical neuroanatomy related to specific neuropsychological deficits in Alzheimer's continuum. Dement Neurocogn Disord. 2019; 18(3): 77-95.
10.12779/dnd.2019.18.3.77
PubMed Google Scholar
21Kang SH, Park YH, Kim JP, et al. Cortical neuroanatomical changes related to specific neuropsychological deficits in subcortical vascular cognitive impairment. Neuroimage Clin. 2021; 30:102685.
10.1016/j.nicl.2021.102685
PubMed Web of Science® Google Scholar
22Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc. 1997; 15: 300-308.
Google Scholar
23Zijdenbos AP, Forghani R, Evans AC. Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging. 2002; 21(10): 1280-1291.
10.1109/TMI.2002.806283
PubMed Web of Science® Google Scholar
24Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002; 17(3): 143-155.
10.1002/hbm.10062
PubMed Web of Science® Google Scholar
25Kwak K, Yoon U, Lee DK, et al. Fully-automated approach to hippocampus segmentation using a graph-cuts algorithm combined with atlas-based segmentation and morphological opening. Magn Reson Imaging. 2013; 31(7): 1190-1196.
10.1016/j.mri.2013.04.008
PubMed Web of Science® Google Scholar
26Bilgel M, An Y, Helphrey J, et al. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain. 2018; 141(8): 2475-2485.
10.1093/brain/awy150
PubMed Web of Science® Google Scholar
27Saxton J, Lopez O l, Ratcliff G, et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004; 63: 2341-2347.
10.1212/01.WNL.0000147470.58328.50
CAS PubMed Web of Science® Google Scholar
28Reiman EM, Caselli RJ, Chen K, et al. Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc Natl Acad Sci USA. 2001; 98(6): 3334-3339.
10.1073/pnas.061509598
CAS PubMed Web of Science® Google Scholar
29Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8): 734-746.
10.1034/j.1600-0404.2003.02021.x
PubMed Web of Science® Google Scholar
30Bilgel M, An Y, Lang A, et al. Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample. Alzheimers Dement. 2014; 10(6): 735-742.
10.1016/j.jalz.2014.04.520
PubMed Web of Science® Google Scholar
31Greenaway MC, Lacritz LH, Binegar D, et al. Patterns of verbal memory performance in mild cognitive impairment, Alzheimer disease, and normal aging. Cogn Behav Neurol. 2006; 19(2): 79-84.
10.1097/01.wnn.0000208290.57370.a3
PubMed Web of Science® Google Scholar
32Jonaitis EM, Koscik RL, Clark LR, et al. Measuring longitudinal cognition: Individual tests versus composites. Alzheimers Dement (Amst). 2019; 11: 74-84.
10.1016/j.dadm.2018.11.006
PubMed Google Scholar
33Mielke MM, Machulda MM, Hagen CE, et al. Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. Alzheimers Dement. 2016; 12(3): 281-291.
10.1016/j.jalz.2015.09.010
PubMed Web of Science® Google Scholar
34Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3): 189-198.
10.1016/0022-3956(75)90026-6
CAS PubMed Web of Science® Google Scholar
35Fillenbaum GG, Wilkinson WE, Welsh KA, Mohs RC. Discrimination between stages of Alzheimer's disease with subsets of Mini-Mental State Examination items. An analysis of Consortium to Establish a Registry for Alzheimer's Disease data. Arch Neurol. 1994; 51(9): 916-921.
10.1001/archneur.1994.00540210088017
CAS PubMed Google Scholar
36Galasko D, Klauber MR, Hofstetter CR, Salmon DP, Lasker B, Thal LJ. The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Arch Neurol. 1990; 47(1): 49-52.
10.1001/archneur.1990.00530010061020
CAS PubMed Web of Science® Google Scholar
37Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999; 122(Pt 5): 871-882.
10.1093/brain/122.5.871
PubMed Web of Science® Google Scholar
38Lim YY, Snyder PJ, Pietrzak RH, et al. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimers Dement (Amst). 2016; 2: 19-26.
10.1016/j.dadm.2015.11.003
PubMed Google Scholar
39Lee JS, Park YH, Park S, et al. Distinct brain regions in physiological and pathological brain aging. Front Aging Neurosci. 2019; 11: 147.
10.3389/fnagi.2019.00147
PubMed Web of Science® Google Scholar
40McDonald CR, McEvoy LK, Gharapetian L, et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology. 2009; 73(6): 457-465.
10.1212/WNL.0b013e3181b16431
CAS PubMed Web of Science® Google Scholar
41Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009; 132(Pt 4): 1067-1077.
CAS PubMed Web of Science® Google Scholar
42Jack CR Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000; 55(4): 484-489.
10.1212/WNL.55.4.484
PubMed Web of Science® Google Scholar
43Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol. 2008; 63(1): 72-80.
10.1002/ana.21296
PubMed Web of Science® Google Scholar
44Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009; 132(Pt 5): 1310-1323.
10.1093/brain/awn320
CAS PubMed Web of Science® Google Scholar
45Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4): 535-562.
10.1016/j.jalz.2018.02.018
PubMed Web of Science® Google Scholar
46Ikonomovic MD, Buckley CJ, Heurling K, et al. Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun. 2016; 4(1): 130.
10.1186/s40478-016-0399-z
PubMed Web of Science® Google Scholar
47Cho SH, Choe YS, Kim YJ, et al. Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments. Sci Rep. 2020; 10(1):19576.
10.1038/s41598-020-76102-5
CAS PubMed Web of Science® Google Scholar
48Kim HR, Choe YS, Moon SH, et al. Finding the optimal cutoff value for amyloid β positivity using the iterative outlier method and concordance rate. Precis Future Med. 2021; 5(2): 83-89.
10.23838/pfm.2021.00023
CAS Web of Science® Google Scholar

Citing Literature

Volume29, Issue4

April 2022

Pages 980-989

Longitudinal amyloid cognitive composite in preclinical Alzheimer’s disease

Abstract

Background and purpose

Methods

Results

Conclusions

CONFLICT OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Longitudinal amyloid cognitive composite in preclinical Alzheimer’s disease

Abstract

Background and purpose

Methods

Results

Conclusions

CONFLICT OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

Supporting Information

REFERENCES

Citing Literature

References

Related

Information